Summary
The clinical manifestations of 131 rheumatic disease patients with anti-Sm antibody were studied. A variety of standard tests was utilized in the study, namely, the FANA test with mouse kidney as substrate for the assay of ANA, the Crithidia test for anti-double stranded DNA (anti-dsDNA) and double immunodiffusion for detecting antibodies to extractable nuclear antigens. The patients were grouped according to the presence of anti-Sm alone, or anti-Sm with some other antibodies. There were 17 with anti-Sm alone; 55 with anti-Sm + anti-RNP; 15 with anti-Sm + anti-dsDNA; and 44 with anti-Sm + anti-RNP. The result of our study showed that although anti-Sm could be found in other diseases, it was exclusively detected in SLE only if anti-dsDNA was also present. Further, the SLE patients with anti-Sm alone had more frequent central nervous system manifestations than other groups of patients. The renal manifestation was observed more frequently in the group of SLE patients with anti-Sm + anti-dsDNA (92.9%). Among other major manifestations, haematologic involvement had a tendency to be less common in the group of patients with anti-Sm alone. The study concludes that the presence of anti-Sm antibody may be of some value to predict the clinical outcome.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Fernandez-Madrid, F., Mattioli, M. Antinuclear antibodies (ANA): Immunologic and clinical significance. Semin Arthritis Rheum 1976, 6, 83–88.
Harmon, C. Antinuclear antibodies in autoimmune disease: Significance and pathogenicity. Med Clin North Am 1985, 69, 547–563.
Tan, E.M., Kunkel, H.G. Characteristic of a soluble nuclear antigen precepitating with wear of patients with systemic lupus erythematosus. J Immunol 1966, 96, 464–471.
Sharp, G.C., Irvin, W.S., May, C.M., Holman, H.R., Mcduffie, F.C., Hess, E.V. Association of antibodies ot RNP and Sm antigens with MCTD, SLE and other rheumatic diseases. N Engl J Med 1976, 295, 1149–1154.
Nothway, J.D., Tan, E.M. Differentiation of antinuclear antibodies giving speckled staining patterns in immunofluorescence. Clin Immunol Immunopathol 1972, 1, 140–154.
Tan, E.M., Cohen, A.S., Fries, J.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus (SLE). Arthritis Rheum 1982, 25, 1271–1277.
Arden, L.A., De Groot, E.R., Feltkamp, T.E.W. Immunology of DNA III Crithidia luciliae, a simple substrate. Proc N Y Acad Sci 1975, 254, 505–514.
Sharp, G.C., Irvin, W.S., Tan, E.M., Gould, R.G., Holman, H.R. Mixed connective tissue disease: an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972, 52, 148–159.
Hamburger, M., Hodes, S., Barland, P. The incidence and clinical significance of antibodies to extractable nuclear antigens. Am J Med Sci 1977, 273, 21–28.
Barada, F.A.Jr., Andrews, B.S., Davis, J.S.I.V., Taylor, R.P. Antibodies to Sm in patients with systemic lupus erythematosus: correlation of Sm antibody titers with disease activity and other laboratory parameters. Arthritis Rheum 1981, 24, 1236–1244.
Winn, D.M., Wolfe, J.F., Lindberg, F.A., Fristoe, F.H., Kingsland, L., Sharp, G.C. Identification of a clinical subset of systemic lupus erythematosus by antibodies to Sm antigen. Arthritis Rheum 1979, 22, 1334–1377.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Janwityanuchit, S., Verasertniyom, O., Vanichapuntu, M. et al. Anti-Sm: Its predictive value in systemic lupus erythematosus. Clin Rheumatol 12, 350–353 (1993). https://doi.org/10.1007/BF02231577
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02231577